Concord Wealth Partners Neurocrine Biosciences Inc Transaction History

Concord Wealth Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Apr 30, 2024	BUY	$94.02 - $117.1 $7,897 - $9,836	84 New	84 $9,000
Q4 2022 Jan 27, 2023	BUY	$106.72 - $127.06 $8,964 - $10,673	84 New	84 $10,000
Q3 2021 Nov 09, 2021	SELL	$86.18 - $99.03 $3,188 - $3,664	-37 Reduced 30.58%	84 $8,000
Q2 2021 Jul 29, 2021	BUY	$89.43 - $102.27 $5,902 - $6,749	66 Added 120.0%	121 $12,000
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $4,816 - $6,567	55 New	55 $5,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.